Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Ovarian Neoplasms × exemestane × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 59 Neoplasm Metastasis 3 Breast Neoplasms, Male 3 Neoplasms 2 Sleep Wake Disorders 1 Ovarian Neoplasms 1 First Line Metastatic Breast Cancer 1 Fatigue 1 Carcinoma, Intraductal, Noninfiltrating 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Breast Cancer Female 1 Advanced Breast Cancer 1

Interventions

Paclitaxel 67 Carboplatin 56 Bevacizumab 28 liposomal doxorubicin 23 Topotecan 22 Gemcitabine 18 olaparib 16 Cisplatin 13 Doxorubicin 12 Drug Therapy 11 Taxes 10 niraparib 9 Docetaxel 6 Trabectedin 5 CP protocol 5 avelumab 4 atezolizumab 4 Immunoglobulin G 4 Ifosfamide 4 Hyperthermic Intraperitoneal Chemotherapy 4 Disulfides 4 Dexamethasone 4 Cyclophosphamide 4 Chemotherapy, Adjuvant 4 1-dodecylpyridoxal 4 trebananib 3 pembrolizumab 3 fluzoparib 3 dostarlimab 3 cediranib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04460807 2024-02-12

EXPERT

Ente Ospedaliero Ospedali Galliera

Phase 3 Terminated

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡